Critical Care Centre, Coporació Sanitaria Parc Tauli, Sabadell, Spain.
Intensive Care Med. 2013 Apr;39(4):672-81. doi: 10.1007/s00134-012-2808-5. Epub 2013 Jan 29.
As per 2005 American Thoracic Society and Infectious Disease Society of America (ATS/IDSA) guidelines for managing hospital-acquired pneumonia, patients with early-onset pneumonia and without risk factors do not need to be treated for potentially resistant microorganisms (PRM).
This was a secondary analysis of a prospective, observational, cohort, multicentre study conducted in 27 ICUs from nine European countries.
From a total of 689 patients with nosocomial pneumonia who required mechanical ventilation, 485 patients with confirmed etiology and antibiotic susceptibility were further analysed. Of these patients, 152 (31.3 %) were allocated to group 1 with early-onset pneumonia and no risk factors for PRM acquisition, and 333 (68.7 %) were classified into group 2 with early-onset pneumonia with risk factors for PRM or late-onset pneumonia. Group 2 patients were older and had more chronic renal failure and more severe illness (SAPS II score, 44.6 ± 16.5 vs. 47.4 ± 17.8, p = 0.04) than group 1 patients. Trauma patients were more frequent and surgical patients less frequent in group 1 than in group 2 (p < 0.01). In group 1, 77 patients (50.7 %) had PRM in spite of the absence of classic risk factors recognised by the current guidelines. A logistic regression analysis identified that presence of severe sepsis/septic shock (OR = 3.7, 95 % CI 1.5-8.9) and pneumonia developed in centres with greater than 25 % prevalence of PRM (OR = 11.3, 95 % CI 2.1-59.3) were independently associated with PRM in group 1 patients.
In patients admitted to ICUs with a prevalence of PRM greater than 25 % or with severe sepsis/septic shock, empiric therapy for group 1 nosocomial pneumonia requiring mechanical ventilation should also include agents likely to be effective for PRM pathogens.
根据 2005 年美国胸科学会和传染病学会(ATS/IDSA)关于医院获得性肺炎管理的指南,对于早发性肺炎且无危险因素的患者,无需针对潜在耐药微生物(PRM)进行治疗。
这是一项在来自 9 个欧洲国家的 27 个 ICU 进行的前瞻性、观察性、队列、多中心研究的二次分析。
在需要机械通气的 689 例医院获得性肺炎患者中,对有明确病因和抗生素敏感性的 485 例患者进行了进一步分析。这些患者中,152 例(31.3%)被分到第 1 组,为早发性肺炎且无 PRM 获得危险因素的患者,333 例(68.7%)归入第 2 组,为早发性肺炎且有 PRM 或迟发性肺炎危险因素的患者。第 2 组患者年龄较大,慢性肾衰竭更多,病情更严重(SAPS II 评分,44.6±16.5 比 47.4±17.8,p=0.04)。第 1 组中创伤患者更为常见,而手术患者较少(p<0.01)。第 1 组中,尽管没有当前指南中公认的经典危险因素,但仍有 77 例(50.7%)患者存在 PRM。Logistic 回归分析发现,严重脓毒症/感染性休克(OR=3.7,95%CI 1.5-8.9)和 PRM 流行率大于 25%的中心发生的肺炎(OR=11.3,95%CI 2.1-59.3)是第 1 组患者发生 PRM 的独立相关因素。
在 PRM 流行率大于 25%的 ICU 中或发生严重脓毒症/感染性休克的患者中,对于需要机械通气的早发性肺炎患者,经验性治疗也应包括针对 PRM 病原体可能有效的药物。